1. [Prognostic factors of upper tract urothelial carcinoma].
- Author
-
Elalouf V, Klap J, Delongchamps NB, Conquy S, Sibony M, Saighi D, Peyromaure M, Flam T, Zerbib M, and Xylinas E
- Subjects
- Age Distribution, Body Mass Index, Carcinoma, Transitional Cell mortality, Carcinoma, Transitional Cell therapy, Evidence-Based Medicine, Humans, Neoplasm Grading, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local therapy, Neoplasm Staging, Obesity complications, Prognosis, Risk Factors, Sex Distribution, Smoking adverse effects, Ureteral Neoplasms mortality, Ureteral Neoplasms therapy, Carcinoma, Transitional Cell diagnosis, Neoplasm Recurrence, Local diagnosis, Ureteral Neoplasms diagnosis
- Abstract
Introduction: Upper urinary tract urothelial carcinoma (UTUC) is a rare disease. Thus, little evidence-based data are available to guide clinical decision-making. The aim of the study was to provide an overview of the currently available prognostic factors for UTUC., Material and Methods: A systematic literature search was conducted using the PubMed databases to identify original articles regarding prognostic factors in patients with UTUC., Results: We divided the prognostic factors for UTUC in four different categories: clinical factors, preoperative characteristics, intraoperative/surgical factors and postoperative/pathologic factors. Prognostic factors described in order of importance are: tumor stage and grade, lymph node involvement, a concomitant cis, age at the diagnostic, lymphovascular invasion, tumor architecture and necrosis, tumor location and multifocality, gender. The impact of obesity, smoking and other comorbidities (ECOG, ASA) on outcomes has been recently reported but needs to be validated. The endoscopic approach of distal ureter management during radical nephroureterectomy has been shown to be at higher risk of bladder recurrence., Conclusion: The incorporation of such prognosticators into clinical prediction models might help to guide decision-making with regard to timing of surveillance, type of treatment, performance of lymphadenectomy, and consideration of neoadjuvant or adjuvant systemic therapies., (Copyright © 2013. Published by Elsevier Masson SAS.)
- Published
- 2013
- Full Text
- View/download PDF